Santhera's Duchenne effort gets a boost on positive PhIIa for alternative steroid vamorolone — though there's a lot left to prove

Months after Santhera got its hands on a second Duchenne muscular dystrophy drug, the Swiss company is getting an early look at how it improves muscle function. But serious questions remain as it takes on a field stuffed with entrenched rivals and controversy.